One of the largest dollar figures buried in the proposed 2027 outpatient rule has almost nothing to do with an operating room, yet it could affect the competitive economics surrounding every independent surgery center.

CMS proposes paying certain 340B-acquired drugs at Average Sales Price minus 33.4% in 2027. CMS estimates that this would reduce Original Medicare drug payments by approximately $4.55 billion and beneficiary drug cost-sharing by approximately $1.15 billion in the first year. Because the change must be implemented in a budget-neutral fashion, CMS proposes redistributing an equivalent amount into OPPS payment for non-drug services.

Then comes another twist.

CMS is already recovering excess non-drug payments made between 2018 and 2022 as a consequence of the earlier 340B payment policy. The current mechanism reduces the OPPS conversion factor by 0.5%. For 2027, CMS proposes accelerating that offset to 3%, with the reduction continuing until CMS recovers an estimated $7.8 billion, which the agency projects could occur in 2029. Certain hospitals enrolled after January 1, 2018, would remain excluded from the adjustment.

Why should an ASC owner care about a hospital drug policy?

Because hospitals do not run service lines in financial isolation. A multibillion-dollar change in outpatient drug economics can affect capital allocation, physician alignment, acquisition strategy, service-line priorities and the willingness of hospital systems to subsidize less profitable activities.

Independent ASCs should always watch where hospital margins are being squeezed. The hospital across town is not merely a clinical competitor. It is a portfolio of businesses, and changes in one highly profitable business can influence behavior elsewhere.

The proposed policy is not final. But $5.7 billion in combined Medicare and beneficiary drug-payment reductions is large enough to get anyone’s attention.

In surgery, we watch blood loss by the milliliter. In healthcare finance, occasionally it pays to watch it by the billion.